Regulating Biocompatibility of Carbon Spheres via Defined Nanoscale Chemistry and a Careful Selection of Surface Functionalities

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Misra, Santosh K ^a,b   Chang, Huei Huei ^a,b   Mukherjee, Prabuddha ^a   Tiwari, Saumya ^a   Ohoka, Ayako ^a,b   Pan, Dipanjan ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b CARLE FOUNDATION HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; CARBON; NANOSPHERE;

CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; LD50; MOLECULAR WEIGHT; PARTICLE SIZE; SURFACE PROPERTY; SYNTHESIS; ULTRASTRUCTURE;

BIOCOMPATIBLE MATERIALS; CARBON; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LETHAL DOSE 50; MOLECULAR WEIGHT; NANOSPHERES; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84944345305     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14986     Document Type: Article

References (41)

1. Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F. & Farokhzad, O. C. Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem. Soc. Rev. 41, 2971-3010 (2012).
2. Li, K. & Liu, B. Polymer-encapsulated organic nanoparticles for fluorescence and photoacoustic imaging. Chem. Soc. Rev. 43, 6570-6597 (2014).
3. Jain, P., Huang, X., El-Sayed, I. & El-Sayed, M. Noble metals on the nanoscale: Optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. Acc. Chem. Res. 41, 1578-1586 (2008).
4. Huang, X., El-Sayed, I., Qian, W. & El-Sayed, M. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Am. Chem. Soc. 128, 2115-2120 (2006).
5. Moghimi, S., Hunter, A. & Murray, J. Nanomedicine: Current status and future prospects. FASEB J. 19, 311-330 (2005).
6. Zhang, L. et al. Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761-769 (2008).
7. Yah, C., Simate, G. & Iyuke, S. Nanoparticles toxicity and their routes of exposures. Pak. J. Pharm. Sci. 25, 477 (2012).
8. Qureshi, S. & Medzhitov, R. Toll-like receptors and their role in experimental models of microbial infection. Genes Immun. 4, 87-94 (2003).
9. Kraft, J., Freeling, J., Wang, Z. & Ho, R. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J. Pharm. Sci. 103, 29-52 (2014).
10. Dash, B. et al. The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility. Biomaterials 31, 8188-8197 (2010).
11. Hamad, I. et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphereserum interface: Implications for stealth nanoparticle engineering. ACS Nano 4, 6629-6638 (2010).
12. Salvador-Morales, C., Zhang, L., Langer, R. & Farokhzad, O. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 30, 2231-2240 (2009).
13. Rolland, A., Collet, B., Le Verge, R. & Toujas, L. Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice. J. Pharm. Sci. 78, 481-484 (1989).
14. Dobrovolskaia, M. & McNeil, S. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2, 469-478 (2007).
15. Andersen, A. et al. Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano 7, 1108-1119 (2013).
16. Hooshmand, S. et al. Effects of agave nectar versus sucrose on weight gain, adiposity, blood glucose, insulin, and lipid responses in mice. J. Med. Food 17, 1017-1021 (2014).
17. Bhagat, K. B. D., Patil, P. & Paknikar, K. Hydrothermal synthesis and characterization of carbon nanospheres: a mechanistic insight. RSC Adv. 5, 59491-59494 (2015).
18. Wu, L. et al. A green synthesis of carbon nanoparticle from honey for real-time photoacoustic imaging. Nano Res. 6, 312-325 (2013).
19. Sharma, M. Understanding the mechanism of toxicity of carbon nanoparticles in humans in the new millennium: A systemic review. Indian J. Occup. Environ. Med., 14, 3-5 (2010).
20. Godbey, K. K., Wu, W. T. & Mikos, A. G. Poly(ethyleneimine)-mediated gene delivery affects endothelial cell function and viability. Biomaterials 22, 471-480 (2001).
21. Xue, S., Liu, H. Y. & Wong, H. L. Nanotoxicity: a key obstacle to clinical translation of sirna-based nanomedicine. Nanomedicine (Lond). 9, 295-312 (2014).
22. Fischer, D., Bieber, Y., Li, T. & Kissel, T. A novel non-viral vector for dna delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res. 16, 1273-1279 (1999).
23. Jäger, M., Schubert, S. F. D., Ochrimenko, S. & Schubert, U. S. Branched and linear poly(ethylene imine)-based conjugates: synthetic modification, characterization, and application. Chem. Soc. Rev. 41, 4755-4767 (2012).
24. Merkel, O. M. et al. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. Biomaterials 32, 4936-4942 (2011).
25. Pasut, G. & Veronese, F. M. State of the art in pegylation: the great versatility achieved after forty years of research. J. Control. Release 161, 461-472 (2012).
26. Moghimi, S. M. et al. Complement activation cascade triggered by peg-pl engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Control. Release 146, 175-181 (2010).
27. Plank, C., Mechtler, K., Szoka, J. F. C. & Wagner, E. Activation of the complement system by synthetic dna complexes: A potential barrier for intravenous gene delivery. Hum. Gene Ther. 7, 1437-1446 (1996).
28. Mukherjee, S. P., M., D. & Byrne, H. J. In vitro mammalian cytotoxicological study of pamam dendrimers-towards quantitative structure activity relationships. Toxicol. in Vitro 24, 169-177 (2010).
29. Naha, M. L. F. M., Davoren, P. C. & Byrne, H. J. Reactive oxygen species (ros) induced cytokine production and cytotoxicity of pamam dendrimers in j774a.1 cells. Toxicol. Appl. Pharmacol. 246, 91-99 (2010).
30. McNerny, D. Q., Leroueil, P. R. & Baker, J. R. Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals. Nanomed. Nanobiotechnol. 2, 249-259 (2010).
31. Fröhlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomedicine 7, 5577-5591 (2012).
32. Zeng, X., Morgenstern, R. & Nyström, A. M. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing gst-mediated drug resistance. Biomaterials 35, 1227-1239 (2014).
33. Parkin, J. & Cohen, B. An overview of the immune system. Lancet 357, 1777-1789 (2001).
34. Walport, M. Advances in immunology: Complement (first of two parts). N. Engl. J. Med. 344, 1058-1066 (2001).
35. Pham, C. et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J. Biol. Chem. 286, 123-130 (2011).
36. Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. Complement: A key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797 (2010).
37. Moghimi, S. et al. Material properties in complement activation. Adv. Drug Delivery Rev. 63, 1000-1007 (2011).
38. Moghimi, S. & Szebeni, J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42, 463-478 (2003).
39. Chonn, A., Cullis, P. & Devine, D. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146, 4234-4241 (1991).
40. Merkel, O. M. et al. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. Biomaterials 32, 4936-4942 (2011).
41. Ogris, M., Brunner, S., Schüller, S., Kircheis, R. & Wagner, E. PEGylated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6, 595-605 (1999).